Cytoreductive surgery and HIPEC after neoadjuvant chemotherapy for advanced epithelial ovarian cancer

Table 1 Clinical characteristics of the ovarian cancer patients

Patient	Age (yr)	BMI (kg/m2)	Stage	Histology	Grade	PCI	No. of cycle NACT	Clinical response (%)	CC
1	47	23	IIIC	Sierous	3	15	4	100	0
2	50	31	IV	Sierous	3	12	4	> 50	0
3	53	31	IV	Endometrioid	3	6	4	100	0
4	65	19	IIIC	Sierous	2	8	4	> 50	0
5	55	24	IIIC	Sierous	3	21	4	100	0
6	55	21	IIIC	Undifferentiated	3	28	4	< 50	0
7	47	22	IIIC	Endometrioid	3	5	3	> 50	0
8	62	22.9	IIIC	Sierous	3	14	6	> 50	0
9	65	20	IIIC	Sierous	3	13	3	> 50	0

BMI: Body mass index; PCI: Peritoneal cancer index; NACT: Neoadjuvant chemotherapy.

Table 2 Postoperative adverse events n (%)

	Patients	CTCAE grade	Treatment
Postoperative death	0 (0)
Reoperation	1 (11)
Types of complications	5 (56)
Grade 3-5 morbidity	5 (56)
Pelvic abscess	1 (11)	3	Reoperation
Leukopenia	3 (33)	3	G-CSF
Thrombocytopenia	2 (22)	3	Observation

G-CSF: Granulocyte colony-stimulating factor.

Table 3 Studies on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in upfront setting

Ref.	Patients (neoadjuvant)	Type of NACT	HIPEC (technique, drug and dose, temperature, lenght of infusion time)	Period	Country
Steller et al[46]	2		C, carboplatin 800-1200 mg/m2, 41-43 °C, 90 min	NR	United States
Look et al[44]	4		O, doxorubicin, NR, NR	1988-2001	Singapore
Piso et al[45]	8 (1)	iv TPB	O, cisplatin 75 mg/m2, NR, 90 min	1995-1999	Germany
Reichman et al[43]	9 (9)	iv PB	O, cisplatin 50 mg/m2, 40 °C, 90 min	2001-2004	United States
Rufián et al[42]	19		O, paclitaxel 60 mg/m2, 41-43 °C, 60 min	1997-2004	Spain
Roviello et al[47]	45 (31)	iv TPB	C, mitomycin C 25 mg/m2 + cisplatin 100 mg/m2, 41-43 °C, 60 min	2000-2009	Italy
Pavlov et al[39]	31		C, doxorubicin 0.1 mg/kg (+ EPIC 15 mg/m2× 5 d), NR, NR	1995-2007	Serbia
Guardiola et al[40]	31 (31)	iv TPB	O, cisplatin 180 mg, 37 °C, 120min	2003-2006	France
Di Giorgio et al[41]	22 (4)	iv TPB	C, cisplatin 75 mg/m2, 42-43 °C, 60 min	2000-2007	Italy
Lim et al[48]	30 (14)	NR	C, cisplatin 75 mg/m2, 41.5 °C, 90 min	2007-2009	Korea
Frenel et al[49]	7 (7)	iv TPB	O, oxaliplatin, 360-460 mg/m2, 41-43 °C, 30 min	2005-2008	France
Muñoz-Casares et al[50]	10 (10)	ip TB (+ in 5 pts iv PB)	O, paclitaxel, 60 mg/m2, 41-43 °C, NR	2004-2009	Spain
Parson et al[38]	51		C, carboplatin 1000 mg +mitomycin C 30 mg, 41-42 °C, 60-120 min	1996-2009	United States
Deraco et al[32]	26		C, cisplatin 40 mg/L of perfusate + doxorubicin 15 mg/L of perfusate), 42.5 °C, 90 min	2004-2010	Italy

NACT: Neoadjuvant chemotherapy; O: Open method; C: Closed method; TPB: Taxanes and platinum based; PB: Platinum based; TB: Taxanes based; NR: Not reported; HIPEC: Hyperthermic intraperitoneal chemotherapy.